Phase I trials of high-dose cytosine arabinoside (HDara-C) and HDara-C plus cisplatin in patients with advanced malignancies. 1985

H B Muss, and R L Capizzi, and J N Atkins, and B L Powell, and M R Cooper, and D Ferree, and R A McMahan, and V Jobson, and J Craig, and H D Homesley

UI MeSH Term Description Entries
D007674 Kidney Diseases Pathological processes of the KIDNEY or its component tissues. Disease, Kidney,Diseases, Kidney,Kidney Disease
D007970 Leukopenia A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000). Leukocytopenia,Leukocytopenias,Leukopenias
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005221 Fatigue The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli. Lassitude
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

H B Muss, and R L Capizzi, and J N Atkins, and B L Powell, and M R Cooper, and D Ferree, and R A McMahan, and V Jobson, and J Craig, and H D Homesley
October 1987, Tumori,
H B Muss, and R L Capizzi, and J N Atkins, and B L Powell, and M R Cooper, and D Ferree, and R A McMahan, and V Jobson, and J Craig, and H D Homesley
September 1995, European journal of haematology,
H B Muss, and R L Capizzi, and J N Atkins, and B L Powell, and M R Cooper, and D Ferree, and R A McMahan, and V Jobson, and J Craig, and H D Homesley
March 1985, Cancer,
H B Muss, and R L Capizzi, and J N Atkins, and B L Powell, and M R Cooper, and D Ferree, and R A McMahan, and V Jobson, and J Craig, and H D Homesley
June 1985, Seminars in oncology,
H B Muss, and R L Capizzi, and J N Atkins, and B L Powell, and M R Cooper, and D Ferree, and R A McMahan, and V Jobson, and J Craig, and H D Homesley
January 1984, Journal of neuro-oncology,
H B Muss, and R L Capizzi, and J N Atkins, and B L Powell, and M R Cooper, and D Ferree, and R A McMahan, and V Jobson, and J Craig, and H D Homesley
February 1985, Onkologie,
H B Muss, and R L Capizzi, and J N Atkins, and B L Powell, and M R Cooper, and D Ferree, and R A McMahan, and V Jobson, and J Craig, and H D Homesley
January 2003, Cancer investigation,
H B Muss, and R L Capizzi, and J N Atkins, and B L Powell, and M R Cooper, and D Ferree, and R A McMahan, and V Jobson, and J Craig, and H D Homesley
August 1979, Cancer treatment reports,
H B Muss, and R L Capizzi, and J N Atkins, and B L Powell, and M R Cooper, and D Ferree, and R A McMahan, and V Jobson, and J Craig, and H D Homesley
December 2009, American journal of clinical oncology,
H B Muss, and R L Capizzi, and J N Atkins, and B L Powell, and M R Cooper, and D Ferree, and R A McMahan, and V Jobson, and J Craig, and H D Homesley
December 1983, British journal of cancer,
Copied contents to your clipboard!